Close

Passage Bio (PASG) Reports First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/18/2024

1. LVS
2. TSM
3. NFLX
4. CSX
5. SPY
6. UAL
7. ALK
8. EFX
9. TSLA
10. MU


Go back to Passage Bio (PASG) Reports First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
(NASDAQ: PASG) Delayed: 1.20 -0.07 (5.51%)
Previous Close $1.27    52 Week High $ 
Open $1.25    52 Week Low $ 
Day High $1.28    P/E N/A 
Day Low $1.14    EPS $ 
Volume 122,368